Scholars Central

Review articlePublished 11 Jan 2019

Role of N-Acylethanolamines in the Neuroinflammation: Ultramicronized Palmitoylethanolamide in the Relief of Chronic Pain and Neurodegenerative Diseases

Authors: Enza Palazzo, Livio Luongo, Francesca Guida, Vito de Novellis, Serena Boccella, Claudia Cristiano, Ida Marabese, Sabatino Maione

Neuropsychiatry

Volume 9 · Issue 1 · Pages 2035–2046

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Pain and neuroinflammation are protective responses aimed at preventing and removing injurious stimuli. However, when prolonged, they can override the bounds of physiological control and become destructive. Chronic pain and neuroinflammation are critical components in the pathophysiology of neurodegenerative diseases, stroke, spinal cord injury, diabetes, and neuropsychiatric disorders. Natural mechanisms, including the production of lipid mediators, represent an endogenous protective process and a program of resolution stimulated and triggered by tissue injury or inflammation. Lipid mediators include N-acylethanolamines (NAEs) such as palmitoylethanolamide (PEA), an endocannabinoid anandamide congener which has shown to be endowed of neuroprotective and antinflammatory properties activated under several pathological states. PEA does not bind the classical cannabinoid receptors but indirectly stimulates the effects of cannabinoids. Its antinflammatory, analgesic and neuroprotective actions have been however associated with peroxisome proliferator-activated receptor-α (PPAR-α) activation. The administration of exogenous PEA requires parenteral routes owing to its lipid structure. The micronized and ultramicronized (m- and um-) formulation permits oral administration increasing the versatility, easiness and compliance of administrations in clinical studies. This review is intended to deal with the effects of m- and um-PEA on chronic pain and neuroinflammation in several animal models of chronic pain and neudegenerative disorders and in clinical studies.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Neuropsychiatry.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalNeuropsychiatry
  • SubjectNeuroscience & Neurology
  • BylineArticles whose byline prints “Enza Palazzo”
  • BylineArticles whose byline prints “Livio Luongo”
  • BylineArticles whose byline prints “Francesca Guida”
  • BylineArticles whose byline prints “Vito de Novellis”
  • BylineArticles whose byline prints “Serena Boccella”
  • BylineArticles whose byline prints “Claudia Cristiano”
  • BylineArticles whose byline prints “Ida Marabese”
  • BylineArticles whose byline prints “Sabatino Maione”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels